Revisiting the cardiometabolic relevance of serum amylase by Nakajima, Kei et al.
CORRESPONDENCE Open Access
Revisiting the cardiometabolic relevance of serum
amylase
Kei Nakajima
1,3*, Toshitaka Muneyuki
2, Hiromi Munakata
3 and Masafumi Kakei
2
Abstract
Background: The pancreas has dual functions as a digestive organ and as an endocrine organ, by secreting
digestive enzymes and endocrine hormones. Some early studies have revealed that serum amylase levels are lower
in individuals with chronic pancreatitis, severe long-term type 2 diabetes or type 1 diabetes. Regarding this issue,
we recently reported that low serum amylase levels were associated with metabolic syndrome and diabetes in
asymptomatic adults. In the light of this, we further investigated the fundamental relationship between serum
amylase and cardiometabolic aspects by reanalyzing previous data which comprised subjects without diabetes
treatment with oral hypoglycemic drugs or insulin (n = 2,344).
Findings: Serum amylase was inversely correlated with body mass index independently of age. Higher serum
amylase levels were noted in older subjects aged 55 years old or more (n = 1,114) than in younger subjects (P <
0.0001, ANOVA), probably due to lower kidney function. It was likely that serum amylase may act similarly to other
cardiometabolic protective factors such as high-density lipoprotein cholesterol. However, serum amylase levels
were significantly lower in drinkers, particularly daily drinkers (n = 746, P < 0.0001, ANOVA). Meanwhile, despite of
consistent inverse relationship between serum amylase and fasting plasma glucose, the relationship between
serum amylase and HbA1c may be rather complicated in individuals with normal or mildly impaired glucose
metabolism (up to HbA1c 6.0% (NGSP)).
Conclusions: Revisiting the cardiometabolic relevance of serum amylase may yield novel insight not only into
glucose homeostasis and metabolic abnormalities related to obesity, but also possibly carbohydrate absorption in
the gut.
Introduction
In recent years, many studies have provided evidence that
d i g e s t i v eo r g a n sc o n t r i b u t et ot h ec o n t r o lo fe n e r g yb a l -
ance and glucose homeostasis via gut hormones [1]. The
pancreas has dual functions as a digestive organ and as an
endocrine organ, by secreting digestive enzymes including
amylase and endocrine hormones including insulin. The
exocrine-endocrine relationship in the pancreas has been
a focus of much attention in animal and cellular studies
[2]. On the other hand, few clinical studies have been con-
ducted and the clinical relevance of low serum amylase
levels remains unknown, although the impact of high
serum amylase levels has been investigated by numerous
clinical researchers in terms of acute pancreatitis.
Some early studies have revealed that serum amylase
levels are lower in individuals with chronic pancreatitis,
severe long-term type 2 diabetes or type 1 diabetes [3-6],
which are often accompanied by atrophic pancreas tissue.
However, the associations between serum amylase levels
with lifestyle factors and cardiometabolic factors remain
poorly understood. Recently we reported that low serum
amylase levels were associated with metabolic syndrome
and diabetes in asymptomatic adults [7]. Furthermore,
serum amylase levels were lower in smokers, overweight/
obese subjects, and those with a greater number of meta-
bolic syndrome components, compared with each coun-
terpart. We describe other curious findings regarding the
fundamental relationship between serum amylase and car-
diometabolic aspects by reanalyzing the data used in the
previous study. Animal studies have shown that insulin
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improved the secretion of amylase [8-10]. Therefore, this
time, we excluded subjects who answered to the ques-
tioner (medications for diabetes) and who had been trea-
ted with oral hypoglycemic drugs or insulin to rule out the
possible influence of medications on serum amylase and
to better evaluate the relationship between serum amylase
and cardiometabolic risk factors including obesity and
abnormal glucose metabolism.
Methods
As described previously [7], the protocol was approved
by The Ethics Committee of Josai University, and
informed consent was obtained from all participants.
The subjects in this study were asymptomatic Japanese
aged 30-80 years who underwent thorough medical
checkups at Social Insurance Omiya General Hospital,
Saitama, Japan.
Subjects with C-reactive protein ≥ 10.0 mg/l, estimated
glomerular filtration rate (eGFR) ≤ 35 ml/min/1.73 m
2,
serum amylase ≤ 30 IU/l or ≥ 200 IU/l, and those sus-
pected of having cancer or endocrinopathies were
excluded from the study. Furthermore, subjects who had
been treated with oral hypoglycemic drugs or insulin (n =
81, details were unknown) were also excluded. Conse-
quently, a total of 2,344 individuals were included for the
present analysis.
Anthropometric and laboratory measurements were
conducted with standard methods as described previously
[7]. Briefly, the serum amylase level was measured using
an enzymatic method (L-type Amylase, Wako, Tokyo,
Japan) with a normal range of 41-112 IU/l, a detection
limit of 1.7 IU/l, and a run-to-run coefficient of variation
< 5.0%. Plasma glucose and HbA1c were measured by the
glucose oxidase method and by high-performance liquid
chromatography, respectively.
Statistical analysis
The data are expressed as means ± SE. Serum amylase
and high-density lipoprotein cholesterol (HDL-C) were
examined with one-way or two-way analysis of variance
(ANOVA) with six body mass index (BMI) categories as
one factor, and age or drinking alcohol as another fac-
tor. Linear correlation was examined with Pearson’s cor-
relation. Statistical analysis was performed using SPSS
software version 18.0 (SPSS-IBM Chicago, IL). Values of
p < 0.05 were considered statistically significant.
Findings and Discussion
Of cardiometabolic risk factors, high BMI, i.e., overweight/
obesity, is most likely to be associated with low serum
amylase independently of age, as shown in Figure 1, with
an almost linear correlation between serum amylase and
BMI (overall correlation, r = -0.22, P < 0.0001, Pearson’s
correlation). Partial correlation analysis controlling for age
showed similar significant correlation (r = -0.21, P <
0.0001, data not shown). Thus, our subsequent analysis
takes into account BMI. Noteworthy, serum amylase levels
were significantly higher in older subjects aged 55 years
old or more (n = 1,114) than in younger subjects aged 54
years old or less (P < 0.0001, ANOVA), probably due to
lower kidney function in older subjects (serum creatinine
based estimated glomerular filtration rate for older group
and younger group, 71.1 ± 13.0 and 80.5 ± 12.9 ml/min/
1.73 m
2, respectively, P < 0.0001, t-test).
Considering these inverse associations between serum
amylase and unfavorable factors such as obesity and smok-
ing, it is likely that serum amylase may act similarly to
other cardiometabolic protective factors such as HDL and
adiponectin, both of which reflect better insulin sensitivity,
anti-atherogenic and anti-inflammatory properties. Studies
have shown that HDL-C and adiponectin levels are often
elevated in mild to moderate drinkers [11]. Actually, in
our study, HDL-C levels were significantly higher in drin-
kers (Figure 2, P = 0.006, ANOVA). Of note, however, is
that serum amylase levels were significantly lower in drin-
kers, particularly daily drinkers (n = 746, Figure 3, P <
0.0001, ANOVA). This may be the most remarkable dif-
ference regarding alcohol consumption between serum
amylase and HDL-C and adiponectin. Indeed, chronic
mild to moderate alcohol consumption often injures and
attenuates pancreatic functions [12,13], eventually result-
ing in chronic pancreatitis and reduced amylase secretion.
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Figure 1 Relationship between serum amylase and BMI
according to age groups (open circle: younger subjects aged
54 years old or less, closed circle: older subjects aged 55 years
old or more). Statistical difference was examined by two-way
ANOVA and P value was significant at P < 0.0001. The numbers of
subjects in six BMI groups (- 19.0, 19.1-21.0, 21.1-23.0, 23.1-25.0, 25.1-
27.0, and 27.1-kg/m
2) are 157, 371, 638, 566, 330, and 282,
respectively. BMI: body mass index. Bars express standard errors.
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Page 2 of 5In contrast, it has been reported that high alcohol con-
sumption increases the risk of developing type 2 diabetes
[14], which may be related to low serum amylase. How-
ever, the mechanism underlying this link between alcohol
consumption and low serum amylase is unclear.
Our previous study also showed a significant association
between low serum amylase and diabetes, presumably type
2 diabetes [7]. Nevertheless, the relationship between
serum amylase and HbA1c, which reflects overall glucose
metabolism, may be rather complicated. As shown in
Figure 4A, we observed a significant but weak correlation
between serum amylase and fasting glucose levels (r =
-0.14, P < 0.0001, Pearson’s correlation), but not with
HbA1c (r = -0.03, P = 0.12) that is estimated as NGSP
equivalent value calculated by the formula HbA1c (%) =
HbA1c (JDS)(%) + 0.4%, considering the relational expres-
s i o no fH b A 1 c( J D S ) ( % )m e a s u r e db yt h ep r e v i o u sJ a p a -
nese standard substance and measurement methods and
HbA1c [15] (Figure 4B), suggesting that overall glucose
homeostasis is unlikely to be associated with serum
amylase, particularly in individuals with normal or mildly
impaired glucose metabolism (up to HbA1c 6.0%
(NGSP)). A plausible explanation is that mild insulin resis-
tance was almost compensated with hyperinsulinemia,
resulting in euglycemia (normal HbA1c) and relatively
lower serum amylase levels than expected based on BMI.
Moreover, glomerular hyperfiltration, which is often
observed in obese people [16,17] or at early stage of dia-
betic nephropathy [18], might interfere with the observed
associations by excess elimination of circulating amylase
from the kidney. In contrast, moderate to severe insulin
resistance was not compensated with hyperinsulinemia (or
the hypoinsulinemia was already apparent), resulting in
substantially impaired insulin action, overall hyperglyce-
mia (high HbA1c), and very low serum amylase levels.
Other reason for the discrepancy between serum amy-
lase and HbA1c may be that HbA1c reflects glucose meta-
bolism over the preceding 1-2 months, whereas serum
amylase may change rapidly in response to changes in
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Figure 2 Relationship between serum HDL-C and BMI according
to alcohol consumption (open circle: nondrinkers, closed
triangle: occasional drinkers, closed circle: daily drinkers).
Statistical difference was examined by two-way ANOVA and P value
was significant at P = 0.006. BMI: body mass index, HDL-C: high-density
lipoprotein cholesterol. Bars express standard errors.
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Figure 3 Relationship between serum amylase and BMI
according to alcohol consumption (open circle: nondrinkers,
closed triangle: occasional drinkers, closed circle: daily
drinkers). Statistical difference was examined by two-way ANOVA
and P value was significant at P < 0.0001. BMI: body mass index.
Bars express standard errors.
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Figure 4 Relationship between serum amylase and fasting
glucose (A), and HbA1c (NGSP) (B). FPG of 90 mg/dl corresponds
with HbA1c of 5.0% (NGSP), as determined by linear regression
analysis between FPG and HbA1c (y = 0.02x + 3.17, where y is
HbA1c and x is FPG; R
2 = 0.44, P < 0.0001). The numbers of subjects
in six BMI groups are the same as those in Figure 1. Statistical
associations were examined by one-way ANOVA and P value is
significant at P < 0.0001 (A). Post hoc analysis with Bonferroni
method showed that no significant difference in serum amylase
was observed between any groups divided with HbA1c (B). BMI:
body mass index, FPG: fasting plasma glucose, NGSP: National
Glycohemoglobin Standardization Program. Bars express standard
errors.
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Page 3 of 5plasma glucose concentration [19]. Zini et al. [10] reported
that low circulating amylase normalized within 1 week of
insulin therapy in cats with diabetes. Furthermore, histolo-
gical examination in their study revealed that low amylase
activities in diabetic cats may reflect an imbalance in glu-
cose metabolism rather than pancreatitis. Nevertheless,
further studies are needed to elucidate the mechanisms
involved in the association.
In terms of the inverse association between serum
amylase and obesity, some explanations are possible.
Reduced insulin action including insulin resistance is a
critical physiological feature accompanied with excess
fat accumulation, primarily in adipose tissues. In this
context, reduced pancreatic amylase secretion might
represent a physiological mechanism designed to reduce
the absorption of carbohydrates by suppressing their
digestion, leading to reduced energy intake. Thus, it is
possible that the pancreas might contribute to the over-
all control of energy balance and glucose homeostasis
not only via its established endocrine effects, but also
via the exocrine system by controlling energy intake
through the small intestine.
There is a growing body of research focusing on pro-
ducts that slow carbohydrate absorption by inhibition of
a-amylase, which is responsible for their digestion [20,21].
Many clinical studies have shown that a-amylase inhibi-
tors (although not clinically available), most of which are
extracted from plants, can reduce the post-prandial glu-
cose excursions, thus correcting abnormal glucose meta-
bolism and prevention of type 2 diabetes [20,21].
Meanwhile, several studies have reported the possibility
that alpha-amylase is produced by some nonpancreatic
gastrointestinal organs such as stomach [22,23], although
controversy still remains. Therefore, low serum amylase
might reflect the endocrine-gastrointestinal system, rather
than the endocrine-exocrine system in the pancreas.
Nevertheless, to our knowledge, no studies have examined
the expression of a-amylase in the intestine or the secre-
tion of a-amylase from the intestine in patients with type
2 diabetes. If expression or secretion of a-amylase in the
gut is actually reduced in patients with type 2 diabetes, it
is likely that a-amylase inhibitors, once approved, and
acarbose, which inhibits both a-glucosidases and pancrea-
tic a-amylase, should be given to people before the reduc-
tions in pancreatic amylase occur.
Regarding the possible role of serum amylase in clinical
practice, collectively, low serum amylase may reflect the
pathophysiological condition of obesity, a fundamental
c a u s eo fM e t S ,w h i c hi sm o s t l yc a u s e db ye n e r g yi m b a l -
ance between food intake and physical activities. On the
other hand, high serum amylase may reflect thinness, i.e.,
possible energy shortage, and kidney dysfunction.
In conclusion, revisiting the cardiometabolic relevance
of serum amylase may yield novel insight not only into
glucose homeostasis and metabolic abnormalities related
to obesity, but also carbohydrate absorption in the gut.
Nevertheless, this hypothesis remains to be tested in
future clinical and animal studies considering insulin
resistance and energy imbalance.
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